Shanghai Best-Link Bioscience

Company snapshot

Shanghai Best-Link Bioscience is a pharma organization headquartered in CN. Primary therapeutic focus areas include Small Cell Carcinoma of Lung. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai Best-Link Bioscience. Not investment advice.

• What is Shanghai Best-Link Bioscience?

  Shanghai Best-Link Bioscience is a pharma organization headquartered in CN. Primary therapeutic focus areas include Small Cell Carcinoma of Lung. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTri

• Is Shanghai Best-Link Bioscience publicly traded?

  Shanghai Best-Link Bioscience appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai Best-Link Bioscience develop or market?

  We link 1 drug profile(s) where Shanghai Best-Link Bioscience is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/link-medical-products-pty-ltd#company-drugs.

• What are the latest developments for Shanghai Best-Link Bioscience?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai Best-Link Bioscience focus on?

  Shanghai Best-Link Bioscience focuses on Small Cell Carcinoma of Lung based on our analysis of their pipeline programs and drug development activities.